TABLE 2.

Clinical features of 22 patients with angiosarcoma of the head and neck: comparison between patients with high plasma fibrinogen (≥257 mg/dL) and low plasma fibrinogen (<257 mg/dL)

Clinical feature	Patient group			P value*
	Total	High plasma fibrinogen group (≥257 mg/dL)	Low plasma fibrinogen group (<257 mg/dL)
Total no. of patients (%)	22 (100)	17 (77)	5 (23)
Age (y)
Median (range)	76 (62‐86)	76 (62‐86)	76 (68‐81)	.813
IQR	68.5, 79	67, 79	72, 79
Sex	No. of patients (%)
Male	15 (68)	10 (59)	5 (100)	.135
Female	7 (32)	7 (41)	0 (0)
ECOG‐PS score
0‐1	19 (86)	15 (88)	4 (80)	1.000
2‐4	3 (14)	2 (12)	1 (20)
Primary site
Head	21 (95)	16 (94)	5 (100)	1.000
Face/neck	1 (5)	1 (6)	0 (0)
T stage
T1	6 (27)	4 (24)	2 (40)	.585
T2	16 (73)	13 (76)	3 (60)
T3	0 (0)	0 (0)	0 (0)
N stage
N0	20 (91)	16 (94)	4 (80)	.411
N1	2 (9)	1 (6)	1 (20)
M stage
M0	21 (95)	16 (94)	5 (100)	1.000
M1	1 (5)	1 (6)	0 (0)
TNM stage
Ⅰ	3 (14)	2 (12)	1 (20)	.489
Ⅱ	16 (73)	13 (76)	3 (60)
Ⅲa	0 (0)	0 (0)	0 (0)
Ⅲb	2 (9)	1 (6)	1 (20)
Ⅳ	1 (5)	1 (6)	0 (0)
Outcome
Alive	13 (59)	12 (71)	1 (20)	.116
Dead	9 (41)	5 (29)	4 (80)
Months of follow‐up
Median (range)	26.1 (2.3‐129.7)	27.0 (2.3‐129.7)	17.8 (8.7‐38.7)	.0583
IQR	14.4, 55.8	23.4, 58.0	10.3, 18.2
Treatment	No. of patients (%)
Surgery	11 (50)	9 (53)	2 (40)	.939
Radiation	20 (91)	15 (88)	5 (100)
IL‐2	7 (32)	5 (29)	2 (40)
Paclitaxel	17 (77)	13 (76)	4 (80)
Docetaxel	5 (23)	4 (24)	1 (20)
Pazopanib	6 (27)	6 (35)	0 (0)
Eribulin	2 (9)	2 (12)	0 (0)
Doxorubicin	1 (5)	1 (6)	0 (0)

Abbreviations: IL‐2, interleukin‐2; IQR, interquartile range; PS, performance status.

^*Statistically significant: P < .05.